HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Pearson, E. R. Articles by Hattersley, A. T. Search for Related Content PubMed PubMed Citation Articles by Pearson, E. R. Articles by Hattersley, A. T. Social Bookmarking                What's this?

Contrasting Diabetes Phenotypes Associated With Hepatocyte Nuclear Factor-1 and -1ß Mutations

¹ Diabetes and Vascular Medicine, Peninsula Medical School, Exeter, U.K
² Department of Endocrinology, Hammersmith Hospital, London, U.K
³ Regional Endocrine Laboratories, University Hospital Birmingham NHS Trust, Birmingham, U.K

Address correspondence and reprint requests to Professor A. Hattersley, Diabetes and Vascular Medicine, Peninsula Medical School, Barrack Road, Exeter, EX2 5AX, U.K. E-mail: a.t.hattersley{at}ex.ac.uk

OBJECTIVE—Mutations in the highly homologous transcription factors hepatocyte nuclear factor (HNF)-1 and -1ß cause maturity-onset diabetes of the young types 3 and 5, respectively. Diabetes due to HNF-1 mutations is well characterized. However, physiological assessment of the HNF-1ß phenotype is limited. We aimed to test the hypothesis that the diabetes phenotype due to HNF-1ß mutations is similar to that in HNF-1.

RESEARCH DESIGN AND METHODS—Fasting biochemistry and a tolbutamide-modified intravenous glucose tolerance test (IVGTT) were compared in matched HNF-1ß, HNF-1, type 2 diabetic, and control subjects. Homeostasis model assessment indexes were determined from fasting insulin and glucose. The peak measures for the insulin increment after tolbutamide and for the insulin increment after glucose were determined from the IVGTT.

RESULTS—The HNF-1ß patients showed a 2.4-fold reduction in insulin sensitivity compared with the HNF-1 patients (P = 0.001) with fasting insulin concentrations 2.7-fold higher (P = 0.004). HNF-1ß patients had lower HDL cholesterol (1.17 vs. 1.46 mmol/l; P = 0.009) and higher triglyceride (2.2 vs. 1.35 mmol/l; P = 0.015) levels than HNF-1 patients. The HNF-1ß patients had similar ß-cell responses to tolbutamide and glucose as the type 2 diabetic patients, but in the HNF-1 patients, the tolbutamide response was considerably increased relative to the response to glucose (P = 0.002).

CONCLUSIONS—HNF-1ß patients have a different diabetes phenotype than HNF-1 patients. Those with HNF-1ß mutations have hyperinsulinemia and associated dyslipidemia consistent with insulin resistance and may have a different ß-cell defect. This suggests that despite considerable homology and a shared binding site, HNF-1 and HNF-1ß have a different role in maintaining normal glucose homeostasis. This result suggests a new etiological pathway for insulin resistance involving HNF-1ß.

Abbreviations: FPG, fasting plasma glucose • HNF, hepatocyte nuclear factor • HOMA, homeostasis model assessment • IDE, insulin-degrading enzyme • IVGTT, intravenous glucose tolerance test • MODY, maturity-onset diabetes of the young • PEAKglu, acute insulin response to glucose • PEAKtolb, acute insulin response to tolbutamide

CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				C. Carette, C. Vaury, A. Barthelemy, S. Clauin, J.-P. Grunfeld, J. Timsit, and C. Bellanne-Chantelot Exonic Duplication of the Hepatocyte Nuclear Factor-1{beta} Gene (Transcription Factor 2, Hepatic) as a Cause of Maturity Onset Diabetes of the Young Type 5 J. Clin. Endocrinol. Metab., July 1, 2007; 92(7): 2844 - 2847. [Abstract] [Full Text] [PDF]

				B. Karges, C. Bergmann, K. Scholl, E. Heinze, F. M. Rasche, K. Zerres, K.-M. Debatin, M. Wabitsch, and W. Karges Digenic Inheritance of Hepatocyte Nuclear Factor-1{alpha} and -1{beta} With Maturity-Onset Diabetes of the Young, Polycystic Thyroid, and Urogenital Malformations Diabetes Care, June 1, 2007; 30(6): 1613 - 1614. [Full Text] [PDF]

				H. J Welters, S. Senkel, L. Klein-Hitpass, S. Erdmann, H. Thomas, L. W Harries, E. R Pearson, C. Bingham, A. T Hattersley, G. U Ryffel, et al. Conditional expression of hepatocyte nuclear factor-1{beta}, the maturity-onset diabetes of the young-5 gene product, influences the viability and functional competence of pancreatic {beta}-cells. J. Endocrinol., July 1, 2006; 190(1): 171 - 181. [Abstract] [Full Text] [PDF]

				A. T. Hattersley and E. R. Pearson Minireview: Pharmacogenetics and Beyond: The Interaction of Therapeutic Response, {beta}-Cell Physiology, and Genetics in Diabetes Endocrinology, June 1, 2006; 147(6): 2657 - 2663. [Abstract] [Full Text] [PDF]

				A. Brackenridge, E. R. Pearson, F. Shojaee-Moradie, A. T. Hattersley, D. Russell-Jones, and A. M. Umpleby Contrasting Insulin Sensitivity of Endogenous Glucose Production Rate in Subjects With Hepatocyte Nuclear Factor-1{beta} and -1{alpha} Mutations Diabetes, February 1, 2006; 55(2): 405 - 411. [Abstract] [Full Text] [PDF]

				E L Edghill, C Bingham, S Ellard, and A T Hattersley Mutations in hepatocyte nuclear factor-1{beta} and their related phenotypes J. Med. Genet., January 1, 2006; 43(1): 84 - 90. [Abstract] [Full Text] [PDF]